Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AZ Labor Tribunal with 3 Employees Falls Apart, Civil Suit to Begin
July 31, 2017
- Rohto to Commence Clinical Trial of Regenerative Medicine Product for Hepatic Cirrhosis
July 31, 2017
- Mitsubishi Tanabe Begins Japan PII/III for Dyskinesia Med
July 28, 2017
- Astellas to Move Away from ADCs, Shuts Agensys Research Operations
July 28, 2017
- 3 Generic Makers Ordered to Pay Damages over Oxarol Patent Infringement
July 28, 2017
- Takeda Gets Rights to Tesaro’s PARP Inhibitor in Japan, Other Markets
July 28, 2017
- Chugai Nets Half-Year Revenue Rise on Milestone Income
July 28, 2017
- Fycompa Approved for Monotherapy for Partial Epilepsy in US
July 28, 2017
- Takeda, BioSurfaces Hook Up on Devices for GI Diseases
July 27, 2017
- Fujifilm to Invest 500 Million Yen in Bonac; Will Engage in Joint Research to Discover Nucleic Acid Medicines
July 27, 2017
- Linzess Off to Solid Start, Astellas Eyes Big Indication Addition
July 26, 2017
- Lenvatinib Filed for HCC in US and EU after Japan Submission
July 26, 2017
- AZ Japan to Work to Create “Frameworks for Success”: Commercial Excellence Head
July 26, 2017
- Sumitomo Dainippon to Invest up to US$10 Million in Investment Partnership
July 26, 2017
- Janssen to Sell Tapenta License to Mundipharma in Japan
July 25, 2017
- Positive Top-Line Data Out for Shionogi’s Sakigake-Designated Flu Med
July 25, 2017
- Boehringer Japan, Kyoto Univ. Seal 2-Year COPD Pact
July 25, 2017
- Novartis Wants to Deliver CAR-T Therapy to Japanese Patients ASAP: Exec
July 25, 2017
- Novartis Japan Revenue Nearly Hit Bottom, FY2016 Sales Down 3.7%: New Chief
July 25, 2017
- (Update) Mitsubishi Tanabe to Buy Israel’s NeuroDerm for US$1.1 Billion
July 25, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…